SLB N.V. (SLB)
Quantitative Summary
DeterministicAt 24.0x earnings — a 31% discount to the sector average of 34.8x — SLB is in the lower valuation range. Financial health is average: Piotroski 4/9, Altman Z 3.2. DCF fair value of $125 implies 141% upside from current prices based on model assumptions.
Generated deterministically from quant metrics and financial statements. Not a recommendation.
Algorithmic Teardown
AI-GeneratedThe fundamental economics of SLB N.V. present a mixed profile characterized by modest capital efficiency and moderate profitability drivers. While the company generates a positive ROIC-WACC spread of +0.9%, indicating value creation above cost of capital, this margin is narrow relative to high-quality peers. The DuPont decomposition reveals that an equity multiplier of 2.01x provides significant leverage support for the current 12.4% ROE; however, this comes at the expense of operational efficiency, evidenced by a low asset turnover ratio of 0.65x and negative revenue growth of -1.6%. Credit metrics offer conflicting signals: an Altman Z-Score of 3.0 suggests moderate bankruptcy risk, while a Beneish M-Score of -2.53 indicates strong earnings quality with minimal manipulation pressure, yet the low Piotroski F-Score of 4/9 underscores structural weaknesses in financial strength and profitability trends over recent periods.
Valuation metrics suggest the market is pricing for significant re-rating potential despite current headwinds. The stock trades at a P/E multiple of 21.0x, which remains below the sector average of 24.0x, implying relative undervaluation within the Energy space. This discount aligns with discounted cash flow models projecting a fair value of $125 and an implied upside of 143.7%, driven by assumptions of low single-digit free cash flow growth averaging just 3.6% over ten years. The divergence between the current market price and DCF-derived targets suggests that investor expectations have already incorporated substantial downside risks, particularly regarding the stagnation in revenue generation and the company's ability to improve asset utilization without increasing leverage further.
Risk-adjusted performance data highlights a challenging recent trajectory for alpha generation. The Fama-French annual alpha of -4.69% indicates underperformance relative to risk factors over the measured period, even as specific factor tilts show promise: the stock exhibits a strong value tilt (HML 0.994) and robust profitability characteristics (RMW 0.241). However, these positive factor exposures are currently outweighed by recent insider activity, which shows $11,828,767 in net selling over the last ninety days. This combination of negative alpha history and active insider divestment warrants scrutiny regarding near-term catalysts needed to validate the higher DCF-based valuations.
Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.
DCF Sandbox
Interactive5-year two-stage DCF. Terminal growth 3%. Default sliders match the pre-computed base case. Drag to explore scenarios. Not investment advice.
The growth rate the market implicitly expects over the next 10 years to justify today's price. Compare with historical growth of -2% YoY revenue.
Sensitivity Matrix
| TG ↓ / WACC → | 6.6% | 8.6% | 10.6% |
|---|---|---|---|
| 2% | $161 | $108 | $80 |
| 3% | $202 | $125 | $89 |
| 4% | $276 | $150 | $101 |
Center = base case. Green = >10% upside, Red = >10% downside vs $56.56.
Pre-computed DCF: WACC=8.6%, terminal growth 3%. Fair value $125 (+141.1%). Not investment advice.
Valuation Context
Currently trading 9% above its 5-year average P/E of 20.3x.
Price Chart with Moving Averages
Technical Setup
AI GeneratedThe stock is trading below its 50-day moving average but above the 200-day moving average, indicating a potential consolidation phase. The RSI at 34.7 suggests that near-term momentum may be weakening and leaning towards bearish territory, as it remains in oversold conditions if dipping further.
Quant Health Deep Dive
Profitability & Value Creation
✅ Conservative payout — room for dividend increases.
DuPont Analysis — ROE Decomposition
Breaking down Return on Equity to see how the company generates its ROE — efficiency, margins, or leverage.
Balance Sheet Health
Insider Activity (Last 90 Days)
Open-market buys vs sells by company insiders. Source: yfinance.
Earnings Surprise History
EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.
Dividend History
| Date | Amount | Change |
|---|---|---|
| 2026-02-11 | $0.2950 | +3.5% |
| 2025-12-03 | $0.2850 | 0.0% |
| 2025-09-03 | $0.2850 | 0.0% |
| 2025-06-04 | $0.2850 | 0.0% |
| 2025-02-05 | $0.2850 | +3.6% |
| 2024-12-04 | $0.2750 | 0.0% |
| 2024-09-04 | $0.2750 | 0.0% |
| 2024-06-05 | $0.2750 | 0.0% |
| 2024-02-06 | $0.2750 | +10.0% |
| 2023-12-05 | $0.2500 | 0.0% |
| 2023-09-05 | $0.2500 | 0.0% |
| 2023-06-06 | $0.2500 | 0.0% |
Dividend and split data from SEC filings and market data. Amounts are per share, not adjusted for splits. Source: yfinance.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Max drawdown = largest peak-to-trough decline. 1,200+ trading days.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this stock's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Fundamentals
Passive Flow Attribution
ETF Draft EffectWhen investors buy or sell ETFs like XLE or XES, the fund manager is mechanically forced to buy or sell SLB shares regardless of SLB N.V.'s individual fundamentals. We estimate $15.4B of passive capital is structurally linked to SLB through 8 tracked ETFs. This substantial passive exposure means that ETF inflows and outflows — not company fundamentals — can dominate daily volume on this stock.
Passive exposure = Σ (ETF AUM × stock weight in ETF) across 8 tracked ETFs. Actual passive ownership is larger (includes mutual funds). Not investment advice.
ETF Contagion Visualizer
Simulate a price drop in SLB N.V. to visualize passive redemption contagion across ETFs and collateral stocks.
If SLB N.V. (SLB) experiences a significant drawdown, ETF redemptions can create collateral selling pressure on co-held stocks. Our model identifies EXXON MOBIL CORP (XOM) as the most exposed collateral stock, sharing 1 ETFs with SLB. This is the "Passive Contagion" effect described in the Inelastic Market Hypothesis.
Contagion model based on shared ETF exposure and constituent weights across 35 tracked ETFs. Estimated selling pressure is a simplified model — actual impact depends on market liquidity, ETF redemption mechanics, and market-maker activity.
SLB Ownership Dynamics
Passive funds hold 1 in every 5 SLB shares, reducing daily market volatility.
SLB N.V. (SLB) exerts notable gravity on the passive index market, currently representing 4.7% of the State Street Energy Select Sector SPDR ETF (XLE) and 4.2% of the XES (XES). Across 34 tracked ETFs, approximately 296M shares (19.8% of float) are held by passive funds and rarely trade on the open market. This level of passive ownership means index rebalances can create outsized volume events.
ETFs with Highest SLB Exposure
Float lock-up computed from 34 ETFs tracked by SecuritiesDB. Actual passive ownership is higher (includes mutual funds, pension funds, etc.).
SLB Institutional Volume Profile
252-day volume distribution by price level. The Point of Control (POC) marks — the price where the most institutional volume transacted — an implicit support/resistance floor.
The highest-volume price zone for SLB N.V. over the past year sits near $34.66 (18% of 252-day volume). The current price of $56.56 trades 63.2% above this institutional floor — a sign of upside momentum, though a pullback to the POC zone is a common reversion target. The highly concentrated volume profile (18% at POC) indicates strong consensus on fair value — institutional participants have repeatedly transacted near this price.
Volume Profile computed from 252 trading days of OHLCV data. Volume allocated to price bins proportionally based on daily high-low range. Not investment advice.
SLB Capital Efficiency
How efficiently does SLB N.V. convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.
SLB N.V. converts 65% of its EBITDA into free cash flow, an exceptional conversion rate indicating an asset-light business model with minimal capital reinvestment drag. The positive ROIC-WACC spread of 0.9% confirms that reinvested capital creates shareholder value.
Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.
Fails-to-Deliver (FTD) History
SEC-reported settlement failures. Elevated FTDs can indicate high short-selling pressure, operational settlement issues, or naked shorting activity.
| Date | Failed Shares | Close Price | Notional Value |
|---|---|---|---|
| 2026-05-11 | 1,000 | $53.27 | $53,270 |
| 2026-05-08 | 3,136 | $53.00 | $166,208 |
| 2026-05-04 | 2 | $56.92 | $113.84 |
| 2026-04-29 | 349,694 | $55.65 | $19.5M |
| 2026-04-28 | 363,742 | $55.23 | $20.1M |
| 2026-04-27 | 100 | $56.15 | $5,615 |
| 2026-04-21 | 37 | $52.20 | $1,931.4 |
| 2026-04-20 | 400 | $52.66 | $21,064 |
| 2026-04-15 | 1,111 | $51.49 | $57,205.39 |
| 2026-04-13 | 133,427 | $51.92 | $6.9M |
| 2026-04-10 | 8,000 | $52.54 | $420,320 |
| 2026-04-07 | 2,448 | $49.78 | $121,861.44 |
| 2026-04-06 | 90,679 | $49.44 | $4.5M |
| 2026-04-01 | 120,151 | $51.39 | $6.2M |
| 2026-03-30 | 8,674 | $53.50 | $464,059 |
| 2026-03-27 | 148,228 | $52.31 | $7.8M |
| 2026-03-25 | 149 | $50.51 | $7,525.99 |
| 2026-03-24 | 49,811 | $49.25 | $2.5M |
| 2026-03-23 | 283,289 | $46.63 | $13.2M |
| 2026-03-20 | 613,456 | $47.82 | $29.3M |
| 2026-03-18 | 11 | $46.13 | $507.43 |
| 2026-03-11 | 791 | $48.11 | $38,055.01 |
| 2026-03-09 | 49,913 | $46.90 | $2.3M |
| 2026-03-06 | 2,458 | $47.40 | $116,509.2 |
| 2026-03-03 | 127,123 | $51.27 | $6.5M |
| 2026-02-23 | 2,000 | $50.85 | $101,700 |
| 2026-02-11 | 44,270 | $50.32 | $2.2M |
| 2026-02-09 | 500 | $50.70 | $25,350 |
| 2026-02-04 | 66 | $49.76 | $3,284.16 |
| 2026-02-02 | 900 | $48.38 | $43,542 |
Source: SEC Regulation SHO FTD data. Data is reported with a ~30 day delay. High FTD quantities relative to average daily volume may indicate settlement stress.
SEC Comment Letters
SEC correspondence with the company regarding their filings. Comment letters often flag disclosure deficiencies, accounting concerns, or material omissions.
Source: SEC EDGAR correspondence. Comment letters are public records of SEC staff review of company filings.
Price Correlations
Statistical correlation of daily returns with other stocks. High correlations indicate stocks that move together; negative correlations can offer diversification.
| Peer | 252-Day (1Y) | 126-Day (6M) | Direction |
|---|---|---|---|
| WTGXX | NaN | NaN | |
| HAL | 0.784 | 0.722 | High co-movement |
| WFRD | 0.776 | 0.747 | High co-movement |
| NOV | 0.744 | 0.678 | High co-movement |
| BKR | 0.687 | 0.718 | Moderate |
| HP | 0.672 | 0.582 | Moderate |
| PTEN | 0.656 | 0.485 | Moderate |
| COP | 0.655 | 0.512 | Moderate |
| WHD | 0.627 | 0.521 | Moderate |
| XOM | 0.624 | 0.515 | Moderate |
Pearson correlation of daily log returns. 252d ≈ 1 trading year. Computed from price history. Not investment advice.
Compare SLB to Peers
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-06-02.
SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.